Market Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson Announces Dividend Increase of 6.1%

Johnson & Johnson (NYSE:JNJ) [PR Newswire] – NEW BRUNSWICK, N.J., April 24, 2014 /PRNewswire/ — Johnson & Johnson (JNJ) today announced that its Board of Directors has declared a 6.1% increase in the quarterly dividend rate, from $0.66 per share to $0.70 per share. The increase was announced this morning at the Annual Meeting of Shareholders in New Brunswick, NJ. “In recognition of our 2013 results, strong financial position and confidence in the future of Johnson & Johnson, the Board has voted to increase the dividend for the 52nd consecutive year,” said Alex Gorsky, Chairman and Chief Executive Officer of the Company. Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. Our approximately 128,300 employees at more than 275 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
Read more on this.

Johnson & Johnson (JNJ), with a current market cap of $282.32B, opened at $100.24.
 
Looking at the equity, the company’s one day range is $99.55 to $100.24 and has traded between $82.12 and $100.75 over the past year.
 
JNJ shares are currently priced at 16.83x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 3.32x earnings multiple.
 
And for income investors, the company pays shareholders $2.64 per share annually in dividends, yielding 2.70%.
 
In a review of the consensus earnings estimate this quarter, 16 sell-side analysts are looking at $1.53 per share, which would be $0.05 better than the year-ago quarter and a $0.02 sequential increase. Investors should also note that the full-year EPS estimate of $5.88 is a $0.36 better when compared to the previous year’s annual results.
 
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $18.79 Billion. If realized, that would be a 5.09% increase over the year-ago quarter.
 
More recently, Barclays downgraded JNJ from Overweight to Equal Weight (Jan 10, 2014). Previously, RBC Capital Mkts upgraded JNJ from Sector Perform to Outperform.
 
When considering if the stock is under or overvalued, the average price target is $104.55, which is 4.30% above where the stock opened this morning.
 
Summary (NYSE:JNJ) :  Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and women’s health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSON’S, AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LUBRIDERM, NEUTROGENA, RoC, VENDÔME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; blood glucose monitoring and insulin delivery products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
 
Tag Helper ~ Stock Code: JNJ | Common Company name: Johnson & Johnson | Full Company name: Johnson & Johnson (NYSE:JNJ) .

More on this topic (What's this?) Read more on JOHNSON & JOHNSON at Wikinvest

NYSE, NASDAQ, Market Data, Earnings Estimates, Analyst Ratings and Key Statistics provided via Yahoo Finance, unless otherwise specified. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Jutia Group will not be liable for any errors, incompleteness or delays, or for any actions taken in reliance on the data displayed herein.

Related Articles


Comments are closed.